0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.